



## **Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7<sup>th</sup>, 2024**

*Conference call scheduled for 9:00 AM ET*

**Rehovot, February 26, 2024 — Evogene Ltd.** (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on **Thursday, March 7<sup>th</sup>, 2024**.

Later that day, Company management will host a **conference call to discuss the results at 9:00 AM Eastern Time** (4:00 PM Israel time).

To join the conference call, please use the following numbers: **+1-888-407-2553** toll-free from the United States or **+972-3- 9180608** internationally. Or at <https://veidan.activetrail.biz/evogeneq4-2023>

A replay of the conference call will be available approximately two hours following the completion of the call. To access the replay, please dial +1-888-326-9310 toll-free from the United States or +972-3-925-5901 internationally. The telephone replay will be accessible for three days, but an archive of the webcast will be available from the webcast link for the following twelve months.

### **About Evogene:**

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - *MicroBoost AI*, *ChemPass AI* and *GeneRator AI*. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (*MicroBoost AI*), small molecules (*ChemPass AI*), and genetic elements (*GeneRator AI*).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:

1. **Biomica Ltd.** ([www.biomicamed.com](http://www.biomicamed.com)) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by *MicroBoost AI*;
2. **Lavie Bio Ltd.** ([www.lavie-bio.com](http://www.lavie-bio.com)) - developing and commercially advancing, microbiome based ag-biologicals powered by *MicroBoost AI*;
3. **AgPlenus Ltd.** ([www.agplenus.com](http://www.agplenus.com)) -developing next generation ag chemicals for effective and sustainable crop protection powered by *ChemPass AI*;
4. **Canonic Ltd.** ([www.canonicbio.com](http://www.canonicbio.com)) – developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by *GeneRator AI*; and
5. **Casterra Ag Ltd.** ([www.casterra.co](http://www.casterra.co))– developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by *GeneRator AI*.

For more information, please visit: [www.evogene.com](http://www.evogene.com).

## Contacts

Rachel Pomerantz Gerber

Head of Investor Relations at Evogene

[rachel.pomerantz@evogene.com](mailto:rachel.pomerantz@evogene.com)

Tel: +972-8-9311901